Serum Leucine-rich alpha-2 glycoprotein was a useful biomarker of endoscopic activity in patients with Crohn’s disease and ulcerative colitis taking Humira, according to a study published in Journal of Gastroenterology.

“[This] study shows that LRG, a novel serum biomarker, better reflects endoscopic activity during adalimumab (Humira; AbbVie) treatment than [c-reactive protein (CRP)] or [fecal calprotectin (fCal)] among [inflammatory bowel disease (IBD)] patients, indicating that LRG can be considered a potential biomarker to monitor disease activity during induction and

Full Article: https://www.healio.com/news/gastroenterology/20210504/serum-lrg-useful-biomarker-of-endoscopic-activity-in-ibd-patients-on-humira